Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes

Tom Lung (), Philip Clarke, Alison Hayes, Richard Stevens and Andrew Farmer

PharmacoEconomics, 2013, vol. 31, issue 6, 509-518

Abstract: The model incorporates diabetic complications risk data from a type 1 diabetes population and synthesizes other type 1—specific data to estimate long-term outcomes of CVD, end-stage renal disease, LEA and risk of blindness, along with life expectancy and QALYs. External validation was carried out using life expectancy and absolute risk for fatal CVD events. Because of the flexible and transparent nature of the model, it has many potential future applications. Copyright Springer International Publishing Switzerland 2013

Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1007/s40273-013-0047-4 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:31:y:2013:i:6:p:509-518

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-013-0047-4

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().